GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Sponsor: Bayer
This observational or N/A phase trial investigates Diabetes Mellitus and is currently completed. Bayer leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2023 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Jul 2023 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Multiple Locations, Algeria , Multiple Locations, Bosnia and Herzegovina , Multiple Locations, Cambodia , Multiple Locations, China , Multiple Locations, Hong Kong , Multiple Locations, India , Multiple Locations, Indonesia , Multiple Locations, Malaysia , Multiple Locations, Moldova , Multiple Locations, Pakistan and 6 more locations